Search

Your search keyword '"Non-small cell lung carcinoma"' showing total 2,110 results

Search Constraints

Start Over You searched for: Descriptor "Non-small cell lung carcinoma" Remove constraint Descriptor: "Non-small cell lung carcinoma"
2,110 results on '"Non-small cell lung carcinoma"'

Search Results

1. Epidermal growth factor receptor-mutated lung carcinomas with insufficient response to epidermal growth factor receptor inhibitors.

2. Clinicopathological Characteristics and Prognosis Analysis of Lung Carcinoma With p40/TTF1 Coexpression and Lung Adenosquamous Carcinoma: Lung Carcinoma With p40/TTF1 Coexpression Is a Rare Tumor With High Metastatic Potential.

3. Deferasirox's Anti-Chemoresistance and Anti-Metastatic Effect on Non-Small Cell Lung Carcinoma.

4. Tetraspanin 3 promotes NSCLC cell proliferation via regulation of β1 integrin intracellular recycling.

5. Pyrogallol Suppresses the Tumor Progression via Modulating Aerobic Glycolysis and STAT2 Signaling Pathway in Non-small Cell Lung Carcinoma.

6. Rare cardiac metastasis of lung cancer mimicking aneurysm and tamponade.

7. Treatment Patterns and Resource Use After Osimertinib Discontinuation in Patients with EGFR + Metastatic NSCLC.

8. Outcomes and Survival for Early-Stage Non-Small Cell Lung Cancer Following Wedge Resection or Lobectomy: A Propensity Score-Matched Analysis Using a Novel Peruvian Registry

9. Tetraspanin 3 promotes NSCLC cell proliferation via regulation of β1 integrin intracellular recycling

10. Different DLCO Parameters as Predictors of Postoperative Pulmonary Complications in Mild Chronic Obstructive Pulmonary Disease Patients with Lung Cancer

11. Treatment Patterns and Resource Use After Osimertinib Discontinuation in Patients with EGFR + Metastatic NSCLC

12. Risk Factor Analysis of Morbidity and 90-Day Mortality of Curative Resection in Patients with Stage IIIA–N2 Non-Small Cell Lung Cancer after Induction Concurrent Chemoradiation Therapy

13. Evaluation of antitumor potential of an anti-glypican-1 monoclonal antibody in preclinical lung cancer models reveals a distinct mechanism of action

14. Proteasome Inhibitor YSY01A Abrogates Constitutive STAT3 Signaling via Down-regulation of Gp130 and JAK2 in Human A549 Lung Cancer Cells.

15. Discordant ALK Status in Non-Small Cell Lung Carcinoma: A Detailed Reevaluation Comparing IHC, FISH, and NGS Analyses.

16. In silico Molecular Docking and Molecular Dynamics Simulation Analysis of Matairesinol with Molecular Targets in Non-Small Cell Lung Carcinoma.

17. HER2 evaluation for clinical decision making in human solid tumours: pearls and pitfalls.

18. Analytical and Clinical Validation of a Highly Sensitive NGS-Based ctDNA Assay with Real-World Concordance in Non-Small Cell Lung Cancer.

19. Non-small cell lung carcinoma with clear cell features: a clinicopathologic, immunohistochemical, and molecular study of 31 cases.

20. Comparing the Effectiveness of Afatinib and Osimertinib for Patients With PD-L1-positive EGFR-mutant Non-small Cell Carcinoma.

21. Solubility, pH-Solubility Profile, pH-Rate Profile, and Kinetic Stability of the Tyrosine Kinase Inhibitor, Alectinib.

22. Unraveling the Impact of Six Pentacyclic Triterpenes Regulating Metabolic Pathways on Lung Carcinoma Cells.

23. Comparison of early patient-reported outcomes between uniportal thoracoscopic segmentectomy and wedge resection for peripheral small-sized non-small-cell lung cancer

24. Exploring histological predictive biomarkers for immune checkpoint inhibitor therapy response in non–small cell lung cancer

25. Progression-free survival estimation of docetaxel-based second-line treatment for advanced non-small cell lung cancer: a pooled analysis from 18 randomized control trials.

26. Efficiency of moderately hypofractionated radiotherapy in NSCLC cell model.

27. Treatment Strategies for Non-Small-Cell Lung Cancer with Comorbid Respiratory Disease; Interstitial Pneumonia, Chronic Obstructive Pulmonary Disease, and Tuberculosis.

28. Comparison of early patient-reported outcomes between uniportal thoracoscopic segmentectomy and wedge resection for peripheral small-sized non-small-cell lung cancer.

29. Clinical Effect of Endosonography on Overall Survival in Patients with Radiological N1 Non-Small Cell Lung Cancer.

30. Revolutionizing Non-Small Cell Lung Cancer Diagnosis: Ultra-High-Sensitive ctDNA Analysis for Detecting Hotspot Mutations with Long-term Stored Plasma.

31. Tissue and Plasma-Based Highly Sensitive Blocker Displacement Amplicon Nanopore Sequencing for EGFR Mutations in Lung Cancer.

32. Dichotomous Effects of Glypican-4 on Cancer Progression and Its Crosstalk with Oncogenes.

33. Impact of KRASG12D subtype and concurrent pathogenic mutations on advanced non-small cell lung cancer outcomes.

35. Immunomodulatory gene polymorphisms in non-small cell lung carcinoma susceptibility and survival

36. Real‐world outcome of crizotinib for anaplastic lymphoma kinase‐positive lung cancer: Multicenter retrospective analysis in South Korea

37. A novel sub-regional radiomics model to predict immunotherapy response in non-small cell lung carcinoma

38. Corrigendum: Proteasome inhibitor YSY01A abrogates constitutive STAT3 signaling via down-regulation of Gp130 and JAK2 in human A549 lung cancer cells.

39. Microbiota Diversity in Non-Small Cell Lung Cancer Gut and Mouth Cavity Microbiota Diversity in Non-Small Cell Lung Cancer Patients

40. Deferasirox’s Anti-Chemoresistance and Anti-Metastatic Effect on Non-Small Cell Lung Carcinoma

42. Real‐world outcome of crizotinib for anaplastic lymphoma kinase‐positive lung cancer: Multicenter retrospective analysis in South Korea.

43. Accuracy of Cytologic vs Histologic Specimens for Assessment of Programmed Cell Death Ligand-1 Expression in Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis.

44. TEP RNA: a new frontier for early diagnosis of NSCLC.

45. A novel sub-regional radiomics model to predict immunotherapy response in non-small cell lung carcinoma.

46. Circulating lung cancer biomarkers: From translational research to clinical practice.

47. Economic evaluation of adjuvant therapy with osimertinib in patients with early-stage non–small cell lung cancer and mutated EGFR.

48. The use of minimal residual disease in thoracic oncology: Gaps between promises and the on‐the‐ground reality of daily practice.

49. Evaluation of adverse drug reactions of chemotherapeutic agents used in advanced non-small cell lung cancer – experience from a rural tertiary care institution in North Eastern India.

50. CyberKnife-based stereotactic radiosurgery or fractionated stereotactic radiotherapy in older patients with brain metastases from non-small cell lung cancer.

Catalog

Books, media, physical & digital resources